On March 30, 2021, the U.S. Food and Drug Administration approved the revised label for daunorubicin and cytarabine to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes in pediatric patients aged one year and older.
Read the Jazz Pharmaceuticals announcement.
Posted 3/31/2021
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
